EMBL Ventures is an independent venture capital investor that manages two Funds with a total of €68 million capital on behalf of major European institutional and private investors. EMBL Ventures' close relationship with the European Molecular Biology Laboratory (EMBL) and its technology transfer organization EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) allows it to finance disruptive technologies in an entrepreneurial start-up environment, aiming ultimately for a transaction with a partner that is seeking to acquire external product innovation. EMBL Ventures is exclusively focused on life-science investments.

"Since their first investment, EMBL Ventures has played a constructive and positive role within Affectis. Providing their extensive network, supporting the company through the board of directors or bringing in new projects, we have developed a fruitful relationship."
Prof. Herbert Stadler; CEO, Affectis Pharmaceuticals, Munich (2002-2010)